FDA Cuts Red Tape, Brings Drug Manufacturing Home

After decades of watching drug manufacturing move overseas, America is finally bringing those jobs back home.

The FDA just launched the PreCheck Pilot Program to fix a problem that's plagued the pharmaceutical industry for years. Companies investing billions to build factories in the U.S. had to wait up to 14 months for post-construction approvals, watching their new facilities sit empty while overseas competitors raced ahead.

That paralysis pushed over 70% of primary drug manufacturing outside U.S. borders. When COVID hit and supply chains collapsed, Americans couldn't get basic medications while thousands of potential manufacturing jobs stayed overseas.

The new program changes everything by giving companies regulatory feedback before they break ground. Instead of building first and hoping for approval later, manufacturers now work directly with FDA experts to prevent compliance mistakes that cause costly delays.

Seven companies are already on board. Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin are building state-of-the-art facilities this summer to make everything from cutting-edge gene therapies to everyday IV bags.

These aren't temporary construction jobs. The first seven participants alone will create thousands of permanent, high-wage careers for scientists, engineers, technicians, and factory operators across American communities.

The Ripple Effect

The program targets generic medicines that make up 90% of all U.S. prescriptions but are mostly manufactured overseas. Bringing production home means parents won't worry whether a factory closure in another country will cut off their child's antibiotics.

The FDA is also prioritizing approval applications for older generic drugs that use domestic supply chains. This creates immediate incentives for companies to choose American manufacturing over foreign facilities.

Local economies will feel the impact for generations. These factory jobs anchor entire communities, supporting nearby businesses and keeping talented workers close to home instead of forcing them to move for career opportunities.

Beyond jobs, the program strengthens national security. When critical medications depend on factories half a world away, supply disruptions become public health emergencies that put American lives at risk.

The initiative works alongside Operation TrialBlazer, which brings clinical research trials back to American soil by modernizing drug development regulations. Together, these programs ensure medical breakthroughs are researched, developed, and manufactured entirely in the U.S.

America is proving it can secure healthcare independence while building a stronger economy, one factory at a time.